Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study

Background: The experience of using consolidation durvalumab in post-concurrent chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in real-world clinical practice, and the factors associated with its efficacy are also unclear. We sought to analyze the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chin-Chou, Chiu, Li-Chung, Ju, Jia-Shiuan, Lin, Yu-Ching, Fang, Yueh-Fu, Yang, Cheng-Ta, Hsu, Ping-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541274/
https://www.ncbi.nlm.nih.gov/pubmed/34696229
http://dx.doi.org/10.3390/vaccines9101122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541274/
https://www.ncbi.nlm.nih.gov/pubmed/34696229
http://dx.doi.org/10.3390/vaccines9101122

Ejemplares similares